You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

376 Results
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2024
Drug
Other Name(s): Lonsurf®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Durvalumab - Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer Following Concurrent Chemoradiation
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
durvalumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    chlorambucil
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
chlorambucil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2018
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    anastrozole
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
anastrozole,
palbociclib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
denosumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2024
Drug
Other Name(s): Alunbrig®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2024
Cancer facts
Dec 2018
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    brigatinib - For the treatment of anaplastic lymphoma kinase-positive locally advanced or metastatic non-small cell lung cancer according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
brigatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Drugs Used:
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet
Jan 2024
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
bevacizumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Guidelines and Advice
Status: In-Review
ID: 7-14
Version: 3
Dec 2018

Pages